Price
No data yet.
Social Signal Score
Analyst Ratings
3 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- James A. Bianco
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 22
- Beta
- -0.01
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -4.29
Financials
Net Income
$-9.22MEBITDA
$-8.73MFree Cash Flow
$-8.77MEPS (diluted)
$-0.14Shares Outstanding (diluted)
63.96M+9901372.6%Operating Expenses
$8.76MCash & Debt
$996.0KReturn of Capital
$2.1KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-30.06M | $-0.63 |
| 2024 | $0.00 | $-21.68M | $-1.21 |
| 2023 | $0.00 | $-8.32M | $-11.29 |
| 2022 | $0.00 | $-14.65M | $-324.48 |
| 2021 | $0.00 | $-22.66M | $-903.03 |
| 2020 | $0.00 | $-38.30M | $-2805.84 |
| 2019 | $0.00 | $-9.13M | $-1532.00 |
| 2018 | $0.00 | $-8.05M | $-5524.99 |
| 2017 | $0.00 | $-11.14M | $-9491.47 |
| 2016 | $0.00 | $-8.08M | $-12950.00 |
| 2015 | $0.00 | $-8.86M | $-14525.00 |
| 2014 | $0.00 | $-4.35M | $-7700.00 |
| 2013 | $0.00 | $-8.29M | $-19600.00 |
| 2011 | $0.00 | $-18.9K | $-124.31 |
Valuation
HURAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
10-92.31%Social Signal Score
Mentions (3)
- Newsprnewswire.com·22d ago·Negative
TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers TAMPA, Fla., Sept. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the U.S. Food and Drug Administration (FDA) has…
View source ↗ - Newsmarketbeat.com·52d ago·Negative
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord TuHURA Biosciences NASDAQ: HURA outlined plans for its late-stage immuno-oncology pipeline at the Canaccord Genuity Growth Conference, highlighting an ongoing Phase III study of IFx in first-line advanced Merkel cell carcinoma, a planned AML trial for its VISTA-inhibiting antibody, and preclinical work on immune-modulating antibody-drug conjugates.
View source ↗ - Newsprnewswire.com·53d ago·Neutral
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update TAMPA, Fla., Aug. 14, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's second quarter ended June 30, 2026, and provided a corporate update.
View source ↗
Earnings
Fri, Nov 13(in 5 weeks)
Consensus estimate $-0.14 per share
Typical surprise -8.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 13$-0.14 vs $-0.15beat
- Fri, May 15$-0.13 vs $-0.12miss
- Tue, Mar 31$-0.13 vs $-0.12miss
- Fri, Nov 14$-0.14 vs $-0.15beat
- Thu, Aug 14$-0.21 vs $-0.14miss
- Thu, May 15$-0.15 vs $-0.13miss
Estimates and results for HURA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by HURA officers and directors.
No open-market trades in the recent filings. All 18 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
18 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Laurel Leehouse · FL15 · disclosed Aug 11, 2025 (29d later)Buy$50,001 - $100,000
- Laurel Leehouse · FL15 · disclosed Jan 7, 2025 (43d later)Buy$1,001 - $15,000
- Laurel Leehouse · FL15 · disclosed Nov 21, 2024 (34d later)Sell$100,001 - $250,000
- Laurel Leehouse · FL15 · disclosed May 25, 2024 (19d later)Buy$100,001 - $250,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.